3.6200 +0.04 (1.12%)
After hours: 6:59PM EDT
|Bid||0.0000 x 1000|
|Ask||0.0000 x 900|
|Day's Range||3.5450 - 3.6780|
|52 Week Range||3.5200 - 64.4000|
|Beta (3Y Monthly)||-0.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors love a turnaround play, and Wall Street is littered with stories of fortunes made betting on troubled companies.In the 1960s, American Express (AXP) was rumored to be near bankruptcy when Warren Buffett famously entered what is now one of his favorite Berkshire Hathaway positions. Apple (AAPL), which became the first U.S. company to hit $1 trillion in market value, absorbed more than a decade of losses during the 1980s and '90s before Steve Jobs helped turn the company around - aided by a $150 million investment from Microsoft (MSFT).But while every beat-up stock is a potential turnaround play, not every company achieves that potential. And losses can mount quickly for a stock that's already up against the ropes. So while you might be tempted to dabble in a potential comeback story or two, beware of some of the most common traps that end in disaster.Sometimes the issue is too much debt; rising interest costs and balloon payments can turn minor business setbacks into major liquidity challenges. Other times, once-powerful consumer brands are brought to their knees by management that's too slow to adapt to evolving consumer tastes.Certain areas of the market can be particularly prone to disasters. Start-up biotech stocks are risky because they're racing against the clock to bring new drugs to market before their cash runs out. Disappointing clinical trial result, in these cases, can cut a stock's value in half (or worse) within days. Chinese stocks are problematic, too, because of sometimes poor visibility and weak corporate governance.Here are 13 stocks to sell if you own them, or avoid if you're on the hunt for the next turnaround story. The companies themselves aren't necessarily an extinction threat, but for varying reasons, they're all on the brink of delivering more disastrous returns. SEE ALSO: Beware the Risks in These 13 Blue-Chip Stocks
The loss of momentum is unfortunate, but not devastating. Part of making a career of day trading is understanding that swings in momentum like this happen, and traders need to be prepared for dry spells. The first step in finding balance while momentum disappears is recognizing when reliable trading setups become less reliable.
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares have been highly volatile of late, with the promise offered by its non-alcoholic steatohepatitis drug cushioning any downside for the stock. ContraVir, a thinly traded nanocap biotech, said Thursday after the close the FDA has given it positive feedback in response to its pre-IND meeting about its NASH pipeline asset CRV431. The positive feedback pertained to preclinical data for CRV431, with the regulatory body agreeing with ContraVir's proposed plan for further preclinical studies to support the development of the asset.
Shares of ContraVir Pharmaceuticals Inc. rocketed 69% in active premarket trading Friday, to bounce off the previous session's record low close, after the biopharmaceutical company said it received "positive feedback" from the U.S. Food and Drug Administration in response to its pre-Investigational New Drug (pre-IND) meeting. Trading volume ballooned to over 760,000 shares, compared with the full-day average of about 1 million shares. The pre-IND meeting was with respect to the development of CRV431 for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH). The company said the feedback supports an IND submission for CRV431. "This IND submission for NASH will be in addition to our current existing IND for hepatitis B virus treatment," Chief Executive Robert Foster said. The stock has plunged 78% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13% and the S&P 500 has advanced 18%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
Shares of ContraVir Pharmaceuticals Inc. suffered a record Tuesday, to cap off a whipsaw week for investors that included upbeat results of a drug study, filings indicating the withdrawal, and a withdrawal of the withdrawal, of a share offering.
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...
June has been an eventful month for ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ). Close on the heels of a 1-for-70 reverse stock split, which became effective June 3, the company has had incremental ...
ContraVir Pharmaceuticals (NASDAQ:CTRV) had a memorable Friday as the company's stock soared off the heels of a successful results regarding one of its treatments for liver disease.Source: Shutterstock The Edison, New Jersey-based pharmaceutical business today unveiled findings from a preclinical study in which CRV431, which is a novel cyclophilin inhibitor, significantly helped to decrease the extent of fibrosis in a second animal model of liver fibrosis. The term fibrosis refers to scarring of the liver, and it is a common symptom of non-alcoholic steatohepatitis (NASH), which causes impaired liver function.ContraVir Pharmaceuticals focuses mostly on developing therapeutic drugs to treat liver disease that arises from NASH. The company said that obeticholic acid (OCA), which is a semi-synthetic bile acid analogue drug, was approved for the treatment of primary biliary cholangitis (PBC), and it is being evaluated in Phase 3 trials by another company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe medication was used by a comparator drug within the study and did not decrease the extent of fibrosis in this study conducted by the company. This industry-standard model requires liver fibrosis to be induced in mice by administering carbon tetrachloride."This is the second animal model, and the fifth study overall, in which CRV431 consistently demonstrated a statistically significant reduction in fibrosis," said Dr. Robert Foster, Chief Executive Officer of ContraVir. "In addition, this study showed that CRV431 reduced fibrosis where OCA, a drug approved for PBC with potential to treat additional liver diseases, such as NASH, did not." More From InvestorPlace * 10 Stocks to Buy That Could Be Takeover Targets * 7 S&P 500 Stocks to Buy That Tore Up Earnings * The 10 Best Stocks for 2019 -- So Far Compare Brokers The post Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today appeared first on InvestorPlace.
Shares of the nano-cap, thinly traded biotech ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday. What Happened ContraVir, which focuses on therapies for liver ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.